April 27, 2026 Regeneron Joins Major Drugmakers in Pricing Concessions Under Trump Agreements for New and Existing Medicines
April 26, 2026 FDA Supports Psychedelic-Based Medicines for Treatment-Resistant Depression, PTSD, and Substance Use Disorders
